NCT01854593View on ClinicalTrials.gov

Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

PHASE4CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

March 31, 2014

Conditions
Proliferative Diabetic RetinopathyDiabetic Traction Retinal DetachmentVitreous Hemorrhage
Interventions
DRUG

Bevacizumab

0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)

PROCEDURE

Vitrectomy

vitrectomy of 25 gauge system.

DEVICE

Sham injection

Sham injection one day before vitrectomy

Trial Locations (1)

101-8309

Surugadai Nihon University Hospital, Tokyo

All Listed Sponsors
lead

Nihon University

OTHER

NCT01854593 - Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy | Biotech Hunter | Biotech Hunter